Top

Published in:

01-11-2020 | Chloroquin | IM - REVIEW

Current treatment of COVID-19 in renal patients: hope or hype?

Authors: Palumbo Roberto, Londrino Francesco, Cordova Emanuela, Gambardella Giorgia, Niscola Pasquale, Dominijanni Sara

Published in: Internal and Emergency Medicine | Issue 8/2020

Abstract

To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.

Wu Z, Mc Googan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. https://doi.org/10.1001/jama.2020.2648(Epub ahead of print)CrossRefPubMedPubMedCentral

Huang C, Wang Y (2020) Li X et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5(Epub 2020 Jan 24)CrossRefPubMed

Alberici F, Delbarba E, Manenti C et al (2020) Management of patients on dialysis and with kidney transplant during SARSCOV- 2 (COVID-19) pandemic in Brescia Italy. Kidney Int Rep. https://doi.org/10.1016/j.ekir.2020.04.001CrossRefPubMedPubMedCentral

Alberici F, Del Barba E, Manenti C et al (2020) Gestione del paziente in dialisi e con trapianto di rene in corso di infezione da coronavirus Covid 19. Giornale Italiano di nefrologia Anno 37:2

Ying-Hui J, Lin C, Zhen-Shun C et al (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7:4

Pan Z, Yanbing D, Xia W et al (2020) The epidemiology, diagnosis and treatment of COVID-19. Antimicrob Agents 55(5):105955CrossRef

Ippolito D, Maino C, Pecorelli A et al (2020) Chest X-ray features of SARS-CoV-2 in the emergency department: a multicenter experience from northern Italian hospitals. Respir Med 170:106036. https://doi.org/10.1016/j.rmed.2020.106036(Online ahead of print)CrossRefPubMedPubMedCentral

Devaux CA, Rolain JM, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105938(Online ahead of print)CrossRefPubMedPubMedCentral

Zhonghua Jie He He Hu Xi Za Zhi, (2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. 43(3):185–188. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009. Chinese

10.

Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimi-Crob Agents. https://doi.org/10.1016/jantimicag.2020.105949(In Press)CrossRef

11.

Cortegiani A, Ingoglia G, Ippolito M et al (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. https://doi.org/10.1016/j.jcrc.2020.03.005CrossRefPubMedPubMedCentral

12.

Colson P, Rolain JM, Lagier JC et al (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105932CrossRefPubMedPubMedCentral

13.

Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72–73. https://doi.org/10.5582/bst.2020.01047CrossRefPubMed

14.

Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237(In Press)CrossRefPubMedPubMedCentral

15.

Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69CrossRefPubMedPubMedCentral

16.

National Health Commission (NHC) & State Administration of Traditional Chinese Medicine (Trial Version 7). Diagnosis and treatment protocol for novel coronavirus pneumonia. https://busanchina-consulate.org/chn/zt/4/P020200310548447287942.pdf. Accessed April 20, 2020

17.

Liu J, Cao R, Xu M et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:1–4. https://doi.org/10.1038/s41421-020-0156-0CrossRefPubMedPubMedCentral

18.

Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 22:S0140-6736(20)31180–6. https://doi.org/10.1016/S0140-6736(20)31180-6

19.

Borba MGS , Almeida Val FF, Sampio VS (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020 3(4):e208857

20.

Retallack H, Di Lullo E, Arias C et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A 113(50):14408–14413 (Epub 2016 Nov 29)CrossRefPubMedPubMedCentral

21.

Madrid PB, Panchal RG, Warren TK et al (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 1(7):317–326. https://doi.org/10.1021/acsinfecdis.5b00030(Epub 2015 May 11)CrossRefPubMed

22.

Arabi YM, Deeb AM, Al-Hameed F et al (2019) Saudi critical care trials group, macrolides in critically ill patients with middle east respiratory syndrome. Int J Infect Dis. 81:184–190. https://doi.org/10.1016/j.ijid.2019.01.041(Epub 2019 Jan 25)CrossRefPubMedPubMedCentral

23.

Hydroxychloroquine vs. Azithromycin for hospitalized patients with suspected or confirmed COVID-19, HAHPS (NCT04329832) Latest version (submitted April 7, 2020) on ClinicalTrials.gov, Accessed May 02, 2020

24.

Azithromycin for COVID-19 Treatment in Outpatients Nationwide, ACTION (NCT04332107) Latest version (submitted April 24, 2020) on ClinicalTrials.gov, Accessed May 02, 2020

25.

Alhazzani W, Møller MH, Arabi YM et al (2020) Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. https://doi.org/10.1097/CCM.0000000000004363(Epub ahead of print)CrossRefPubMedPubMedCentral

26.

Katzung BG, Masters SB, Trevor AJ (2011) Farmacologia generale e clinica. X Edizione Italiana a cura del Prof P. Preziosi. pag 931–961

27.

Chu CM, Cheng VCC, Hung IFN (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252–256CrossRefPubMedPubMedCentral

28.

Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY (2015) Treatment with lopinavir/ritonavir or interferon-ß1b Improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212(12):1904–1913. https://doi.org/10.1093/infdis/jiv392(Epub 2015 Jul 21)CrossRefPubMed

29.

Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir-ritonavir in audults hospitalized with severe COVID-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2001282(Epub ahead of print)CrossRefPubMedPubMedCentral

30.

Arabi YM, Asiri AY, Assiri AM et al (2020) Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two stage group sequential randomized controlled trial. Trials 21(1):8. https://doi.org/10.1186/s13063-019-3846-xCrossRefPubMedPubMedCentral

31.

Bryan T. Alexander, Trevor Van Schoonevald, Erica Stohs et al. (2020) COVID-19 Antiviral and Pharmacotherapy Recommendations. Nebraska Medicine. https://www.nebraskamed.com/sites/default/files/documents/covid-19/covid19-antiviral-pharmacotherapy-recommendations

32.

Yao T-T, Qian J-D, ZhuW Y, Wang-Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease‐19 treatment option. J Med Virol 92(6):556–563. https://doi.org/10.1002/jmv.25729

33.

Lim J, Jeon S, Shin H-Y et al (2020) Case of the index patient who caused tertriary transmission of coronovirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6):e79CrossRefPubMedPubMedCentral

34.

Benn P, Ascar MR (2009) Role of darunavir in the management of HIV infection. HIV/AID (Auckl) 1:31–39

35.

Valencia AG, Rodriguez MT, Magdaleno TF et al (2018) Darunavir/cobicistat showing similar effectiveness as darunavir/ ritonavir monotherapy despite lower trough concentrations. J Int AIDS Soc. https://doi.org/10.1002/jia2.25072CrossRef

36.

Santos JR, Curran A, Navarro-Mercade J et al (2019) Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses 35(6):513–518CrossRefPubMed

37.

Efficacy and safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCov (NCT04252274). Latest version (submitted January 29, 2020) on ClinicalTrials.gov. Accessed May 02, 2020

38.

A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of 2019-nCoV pneumonia. (ChiCTR2000029541) Latest version submitted Febrary 12, 2020 on https://www.chictr.org.cn(Chinese Clinical Trial Registry) Accessed May 02, 2020

39.

Società Italiana di Malattie Infettive e Tropicali (SIMIT) (2020) Vademecum per la cura delle persone con malattia da COVID-19. Edizione 2.0. Gruppo collaborativo – Terapia COVID-19 Lombardia

40.

European Medicines Agency (EMA).Rezolsta https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta. Accessed 02, May 2020

41.

Ribavirin EA (2020) Remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. https://doi.org/10.1016/j.lfs.2020.117592(Epub ahead of print)CrossRef

42.

Mulangu S, Dodd LE, Davey LT et al (2019) A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293–2303. https://doi.org/10.1056/NEJMoal1910993CrossRefPubMed

43.

Agostini ML, Andres EL, Sims AC et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9(2):e00221–e318. https://doi.org/10.1128/mBio.00221-18CrossRefPubMedPubMedCentral

44.

Chan KW, Wong VT, Tang SCW (2020) COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. https://doi.org/10.1142/S01922415X20500378(Epub ahead of print)CrossRefPubMed

45.

Lu CC, Chen MY, Chang YL (2020) Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. https://doi.org/10.1097/JCMA.0000000000000318(Epub ahead of print)CrossRefPubMedPubMedCentral

46.

Holshue ML, DeBolt C (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936CrossRefPubMedPubMedCentral

47.

Scavone C, Brusco S, Bertini M et al (2020) Current pharmacologica treatments for COVID 19: wath’s next. Br J Pharmacol. https://doi.org/10.1111/bph.15072(Epub ahead of print Review)CrossRefPubMedPubMedCentral

48.

EMA provides recommendations on compassionate use of remdesivir for COVID-19. (EMA/152575/2020). Avialable on https://www.ema.europa.eu/en/documents/product-information/rezolsta-epar-product-information.it.pdf. Accessed 02, May 2020

49.

US Food and Drug Administration. Fact sheet for health care providers Emergency Use Authorization (EUA) of remdesivir (GS-5734™). https://www.fda.gov/media/137566/download. Accessed May 1, 2020a

50.

Jordan PC, Stevens SK (2018) Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chem Chemother 26:1–19CrossRef

51.

Ruis C, Brown LK, Roy S et al (2018) Mutagenesis in norovirus in response to Favipiravir treatment. N Engl J Med 379(22):2173–2176. https://doi.org/10.1056/NEjMc1806941CrossRefPubMed

52.

Kerberg R, Lorenz E, Duraffour S et al (2019) Laboratory findings, compassionate use of Favipiravir, and outcome in patients with Ebola virus disease, guinea, 2015—a retrospective observational study. J Infect Dis 220(2):195–202. https://doi.org/10.1093/infdis/jiz078CrossRef

53.

Principi N, Camilloni B, Alunno A et al (2019) Drugs for influenza treatment: is there significant news? Front Med (Lausanne) 6:109. https://doi.org/10.3389/fmed.2019.00109CrossRef

54.

Rocha-Pereira J, Jochmans D, Dallmeier K et al (2012) Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 10(424):777–780. https://doi.org/10.1016/j.bbrc.2012.07.034(Epub 2012 Jul 15)CrossRef

55.

Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Thers 14(1):58–60. https://doi.org/10.5582/ddt.2020.0101CrossRef

56.

Liu C, Qiongqiong Z, Li Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6(3):315–331CrossRefPubMed

57.

Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2020.107512(Epub ahead of print)CrossRefPubMedPubMedCentral

58.

Morra ME, Van Thanh L, Kamel MG et al (2018) Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol 28(3):e1977. https://doi.org/10.1002/rmv.1977

59.

Cantong Z, Shaoyiong H, Fengping Z, Yong D (2020) Controversial treatment: an updated understanding of the coronavirus disease 2019. J Med Virol. https://doi.org/10.1002/jmv.25788

60.

Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA. https://doi.org/10.1001/jama.2020.1585(Epub ahead of print)CrossRefPubMedPubMedCentral

61.

Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. https://doi.org/10.1016/S0140-6736(20)30317-2(published online Feb 7)CrossRefPubMedPubMedCentral

62.

Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994(Epub ahead of print)CrossRefPubMedPubMedCentral

63.

Du B, Qiu HB, Zhan X et al (2020) Pharmacotherapeutics for the new coronavirus pneumonia. 43(3):173–176. Zhonghua Jie He He Hu Xi Za Zhi 43(3):173–176. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.005

64.

Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with Tocilizumab. Accessed 19 Mar 2020

65.

Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. https://doi.org/10.1016/S0140-6736(20)30628-0(Epub ahead of print. PMID 32192578)CrossRefPubMedPubMedCentral

66.

F. Hoffmann-La Roche Ltd. Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalized patients with severe COVID-19 pneumonia [press release]. Basel, Switzerland; Roche; March 19, 2020. https://www.roche.com/dam/jcr:f26cbbb1-999d-42d8-bbea-34f2cf25f4b9/en/19032020-mr-actemra-covid-19-trial-en.pdf. Accessed 2020 Apr 2.

67.

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) (NCT04320615). Latest version (submitted March 23, 2020) on ClinicalTrials.gov, Accessed May 02, 2020

68.

Genentech, Inc, South San Francisco, CA. Actemra use in Coronavirus Disease 2019 (COVID-19) standard reply letter. (2020)

69.

Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19 [press release]. Cambridge, Mass and Tarrytown, NY; Sano-fi: 2020. https://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19. Accessed 2020 Mar 19.

70.

Sobi to initiate a clinical study to evaluate whether anakinra and emapalumab may relieve complications associated with severe COVID-19 disease [press release]. Stock-holm, Sweden; Swedish Orphan Biovitrum AB (publ): 2020. https://www.sobi.com/sites/default/files/pr/202003183346-1.pdf. Accessed 2020 Mar 30

71.

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients (NCT04264858) Latest version (submitted February 8, 2020) on ClinicalTrials.gov, Accessed May 02, 2020

72.

Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial (ChiCTR2000029757) Latest Version (submitted March 9, 2020). https://www.chictr.org.cn

73.

Ronco C, Navalesi P, Vincent JL (2020) Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. Lancet Respir Med 8(3):240–241. https://doi.org/10.1016/S2213-2600(20)30060-6(Epub 2020 Feb 6)CrossRefPubMedPubMedCentral

74.

Ronco C, Reis T, De Rosa S (2020) Coronavirus epidemic and extracorporeal Therapies in intensive care: si vis pace para bellum. Blood Purif. https://doi.org/10.1159/000507039(Epub ahead of print No abstract available)CrossRefPubMed

75.

Zuckier L, Moadel RM, Haramati LB, Freeman L (2020) Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic. J Nucl Med. https://doi.org/10.2967/jnumed.120.245571(Online ahead of print)CrossRefPubMed

76.

Danzi GB, Loffi M, Galeazzi L, Gherbesi E (2020) Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa254(Online ahead of print)CrossRefPubMed

77.

Chu KH, Tsang WK, Tang CS et al (2005) Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 67:698–705CrossRefPubMedPubMedCentral

78.

Jung JY, Park BH, Hong SB et al (2011) Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: a multicenter study. J Crit Care 26:577–585CrossRefPubMed

79.

Cheng Y, Luo R, Wang K et al (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97:829–838CrossRefPubMedPubMedCentral

80.

Mubarak M, Nasri H (2020) COVID-19 nephropathy; an emerging condition caused by novel coronavirus infection. J Nephropathol. https://doi.org/10.34172/jnp.2020.21CrossRef

81.

Hua S, Ming Y, Chen W, Li-Xia Y (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98(1):219–227. https://doi.org/10.1016/j.kint.2020.04.003

82.

Larsen CP, Bourne TD, Wilson JD, et al (2020) Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19). Kidney Int Rep 5(6):935–939. https://doi.org/10.1016/j.ekir.2020.04.002

83.

Kissling S, Rotman S, Gerber C et al (2020) Collapsing glomerulopathy in a COVID-19 patient. Kidney Int 98(1):228–231. https://doi.org/10.1016/j.kint.2020.04.006

84.

Riphagen S, Gomez X, Gonzalez-Martinez C et al (2020) Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395:1607CrossRefPubMedPubMedCentral

Title: Current treatment of COVID-19 in renal patients: hope or hype?
Authors: Palumbo Roberto
Londrino Francesco
Cordova Emanuela
Gambardella Giorgia
Niscola Pasquale
Dominijanni Sara
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keywords: Chloroquin
Azithromycin
Chloroquin
Ritonavir
SARS-CoV-2
COVID-19
Chronic Kidney Disease
Hydroxychloroquine
Published in: Internal and Emergency Medicine / Issue 8/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02510-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Thrombosis centres and AVKs monitoring in COVID-19 pandemic

Utilization of machine-learning models to accurately predict the risk for critical COVID-19

Telemedicine in the acute care setting during the COVID-19 pandemic

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply

From the quarantine diary of an emergency physician: the coronavirus and the dysautonomic storm

Liver transplantation in Italy in the era of COVID 19: reorganizing critical care of recipients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials